{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=29", "query": { "intervention": "Placebo SC Injection", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 835, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T13:46:49.021Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06714955", "title": "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-diabetic Overweight or Obese" ], "interventions": [ { "name": "Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.", "type": "DRUG" }, { "name": "Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.", "type": "DRUG" }, { "name": "Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BrightGene Bio-Medical Technology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2024-10-21", "completion_date": "2025-03-03", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06714955" }, { "nct_id": "NCT00734474", "title": "A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2189265", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo solution", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1202, "start_date": "2008-08", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 35, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Mission Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734474" }, { "nct_id": "NCT05189210", "title": "GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mild to Moderate Alzheimer's Disease" ], "interventions": [ { "name": "GV1001 Placebo", "type": "DRUG" }, { "name": "GV1001 0.56mg", "type": "DRUG" }, { "name": "GV1001 1.12mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GemVax & Kael", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 199, "start_date": "2022-10-05", "completion_date": "2025-04-16", "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 12, "location_summary": "Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Adventura", "state": "Florida" }, { "city": "Greenacres City", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Naples", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05189210" }, { "nct_id": "NCT06602258", "title": "A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "E2814", "type": "DRUG" }, { "name": "Lecanemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 105, "start_date": "2024-09-30", "completion_date": "2027-08-18", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 18, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Bradenton, Florida + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Clermont", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06602258" }, { "nct_id": "NCT04773678", "title": "Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Moderate to Severe Persistent Asthma" ], "interventions": [ { "name": "CBP-201", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Connect Biopharm LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 322, "start_date": "2021-05-11", "completion_date": "2023-09-28", "has_results": false, "last_update_posted_date": "2024-03-29", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 39, "location_summary": "Tucson, Arizona • Huntington Beach, California • Lancaster, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Viejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04773678" }, { "nct_id": "NCT04115293", "title": "Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myasthenia Gravis, Generalized" ], "interventions": [ { "name": "zilucoplan (RA101495)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ra Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 174, "start_date": "2019-09-17", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 37, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115293" }, { "nct_id": "NCT04836182", "title": "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Heart Failure With Reduced Ejection Fraction" ], "interventions": [ { "name": "IONIS-AGT-LRx", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 72, "start_date": "2021-06-08", "completion_date": "2023-01-11", "has_results": false, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Crystal River, Florida • Hialeah, Florida + 6 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Crystal River", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Ypsilanti", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04836182" }, { "nct_id": "NCT02281318", "title": "Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Mepolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SOC", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 556, "start_date": "2014-12-11", "completion_date": "2016-06-10", "has_results": true, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02281318" }, { "nct_id": "NCT03714776", "title": "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mild Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "ISIS 757456", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 25, "start_date": "2019-01-03", "completion_date": "2019-11-13", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 6, "location_summary": "Tustin, California • Port Orange, Florida • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Tustin", "state": "California" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lyndhurst", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03714776" }, { "nct_id": "NCT04565717", "title": "A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonalcoholic Steatohepatitis", "NASH" ], "interventions": [ { "name": "ALN-HSD", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2020-10-09", "completion_date": "2023-12-21", "has_results": false, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-11-03T13:46:49.021Z", "location_count": 7, "location_summary": "Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more", "locations": [ { "city": "Fleming Island", "state": "Florida" }, { "city": "Marrero", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hermitage", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04565717" } ] }